Johnson & Johnson

Johnson & Johnson is a diversified healthcare conglomerate operating through three segments: Consumer Health, Pharmaceuticals, and MedTech. The company develops and sells a wide range of products including over-the-counter medicines, prescription drugs for immunology, oncology, and cardiovascular diseases, as well as medical devices and diagnostics. With a market cap of $538.92 billion, it is one of the largest healthcare companies globally.

Revenue is generated primarily from Pharmaceuticals (about 55%) and MedTech (around 30%), with Consumer Health contributing the remainder. The business model relies on a combination of innovative drug development, patent-protected products, and a broad portfolio of medical devices. Key financial metrics show a gross margin of 67.88% and an operating margin of 27.17%, reflecting strong pricing power and operational efficiency. The company has a significant cash position of $21.69 billion against debt of $54.99 billion.

In the Drug Manufacturers - General industry, Johnson & Johnson competes with Pfizer, Merck, and Novartis. Its competitive advantages include a diversified revenue stream across pharmaceuticals, devices, and consumer products, a robust pipeline, and a global distribution network. The company's EV/EBITDA of 17.48 and P/E of 25.93 indicate a premium valuation relative to peers, supported by consistent free cash flow yield of 3.13%.

Johnson & Johnson serves a broad customer base including hospitals, clinics, physicians, and consumers. Its primary geographic markets are the United States (over 50% of revenue), followed by Europe and Asia-Pacific. The company's products reach millions of patients worldwide, with a strong presence in both developed and emerging markets. Recent quarterly revenues have been stable around $24 billion, with net income averaging $5.26 billion per quarter.

An auto-generated descriptive profile based on company data, for informational purposes only.